<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365077</url>
  </required_header>
  <id_info>
    <org_study_id>CUP2015D001</org_study_id>
    <nct_id>NCT02365077</nct_id>
  </id_info>
  <brief_title>GWAS Identified Susceptibility Loci for Glucocorticoid-induced FHN in the Chinese Population</brief_title>
  <official_title>Genome-wide Association Study Identified Susceptibility Loci for Glucocorticoid-induced Femur Head Necrosis in the Chinese Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a observation clinical trial. We are collecting the patients with glucocorticoid.&#xD;
      They were divided into the experiment group (with femur head necrosis) and control group&#xD;
      (without femur head necrosis).Then, we will analyse the patients' genome with genome-wide&#xD;
      association study (GWAS). Our purpose is to find susceptibility loci for&#xD;
      glucocorticoid-induced femur head necrosis in the Chinese population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Glucocorticoid-induced femur head necrosis</measure>
    <time_frame>1 year</time_frame>
    <description>Hip joint MRI for the patients with a history of taking 1800 mg prednisolone or an equivalent over 4 week.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Femur Head Necrosis</condition>
  <condition>Adverse Effect of Glucocorticoids and Synthetic Analogues</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>The patients of necrosis group was defined by a history of taking 1800 mg prednisolone or an equivalent over 4 week without the symptom of femur head necrosis after 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Necrosis</arm_group_label>
    <description>The patients of necrosis group was defined by a history of taking 1800 mg prednisolone or an equivalent over 4 week with the diagnosis of femur head necrosis.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We will collect 4ml whole blood samples under the consent of patient and extract the genome&#xD;
      from the samples. During the process the blood samples will be collected strickly according&#xD;
      the international guide clinical blood specimen collection.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients coming from the Department of Dermatology Xijing Hospital, Fourth Military Medical&#xD;
        University Xi'an, China&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has given the written informed consent voluntarily;&#xD;
&#xD;
          2. Male or female between 18~60 years;&#xD;
&#xD;
          3. Candidate is clinically diagnosed as avascular osteonecrosis of the femoral head&#xD;
             (ONFH), in reference to the diagnostic criteria set forth by Experts' Consensus on the&#xD;
             Diagnosis and Treatment of Osteonecrosis of the Femoral Head in Adults (edition 2012);&#xD;
&#xD;
          4. Patient with history of glucocorticoid therapy, in form of oral, muscular or vascular&#xD;
             administration, should have total dose equivalent to ≧2000 mg of Prednisone, and&#xD;
             maintain on that dose for ≦3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is not in conformity with diagnostic criteria for ONFH;&#xD;
&#xD;
          2. Patient has a history of trauma in the lower limbs or pelvis;&#xD;
&#xD;
          3. Prolonged addiction to alcohol;&#xD;
&#xD;
          4. Concurrent with renal failure, organ transplant, graft versus host disease,&#xD;
             inflammatory bowel disease, HIV infection or leukemia;&#xD;
&#xD;
          5. Patient with familial idiopathic ONFH;&#xD;
&#xD;
          6. Subject suffers from a fatal disease, with life expectancy &lt; 2 months;&#xD;
&#xD;
          7. Woman of child-bearing potential, who is pregnant, in preparation of pregnancy or&#xD;
             breast-feeding during the study period;&#xD;
&#xD;
          8. Other patients deemed ineligible at the discretion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xijing Hospitial</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2015</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>xjpfW</investigator_full_name>
    <investigator_title>Chief in Department of Dermatology</investigator_title>
  </responsible_party>
  <keyword>Adverse Effect of Glucocorticoids</keyword>
  <keyword>Femur Head Necrosis</keyword>
  <keyword>Susceptibility</keyword>
  <keyword>GWAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Femur Head Necrosis</mesh_term>
    <mesh_term>Necrosis</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

